AR074558A1 - Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3 - Google Patents
Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3Info
- Publication number
- AR074558A1 AR074558A1 ARP090104760A ARP090104760A AR074558A1 AR 074558 A1 AR074558 A1 AR 074558A1 AR P090104760 A ARP090104760 A AR P090104760A AR P090104760 A ARP090104760 A AR P090104760A AR 074558 A1 AR074558 A1 AR 074558A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compounds
- synthesis
- compound
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Espiro azepan oxazolidinonas como bloqueadores del canal de calcio Kv1.3 voltaje dependiente, a composiciones farmacéuticas que contienen estos compuestos, a métodos para preparar los compuestos, a compuestos intermedios útiles para su síntesis. Usos de tales compuestos y composiciones, particularmente a su uso para administrarlos a pacientes para lograr un efecto terapéutico en diabetes y neuropatías inflamatorias, incluyendo enfermedades autoinmunes en las cuales las células T actúan como mediador, tales como artritis reumatoide y esclerosis múltiple. Reivindicación 1: Un compuesto de fórmula (1), o un tautómero, estereoisómero, o una sal farmacológicamente aceptable de cualquiera de los precedentes, caracterizado por la fórmula (1) donde R1 y R2 son independientemente hidrógeno, deuterio, flúor, CF3 o alquilo C1-3, no substituido o substituido con uno o más átomos de flúor; n es 0, 1 ó 2; R3 se selecciona entre halógeno, alquilo C1-3, CF3, CN, NH2, NHAc, OH, OCH3, u OCF3; m es 0 (cero), 1, 2 ó 3; R4 se selecciona entre halógeno, alquilo C1-3, CF3, CN, NH2, NHAc, OH, OCH3, u OCF3, o (R4)m y el anillo fenilo al cual está unido forman un grupo naftilo. Reivindicación 7: Un compuesto de fórmula (2), útil en la síntesis de los compuestos de fórmula (1), donde R1, R2, n y R3 tienen los significados dados en la reivindicación 1. Reivindicación 8: Un compuesto de fórmula (3), útil en la síntesis de los compuestos de fórmula (1), donde R1, R2, n y R3 tienen los significados dados en la reivindicación 1. Reivindicación 9: Un compuesto de fórmula (4), útil en la síntesis de los compuestos de fórmula (1), donde R1, R2, n y R3 tienen los significados dados en la reivindicación 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08171421 | 2008-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074558A1 true AR074558A1 (es) | 2011-01-26 |
Family
ID=40513443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104760A AR074558A1 (es) | 2008-12-12 | 2009-12-09 | Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8575148B2 (es) |
| EP (1) | EP2376501A1 (es) |
| JP (1) | JP2012511546A (es) |
| KR (1) | KR20110110165A (es) |
| CN (1) | CN102333782A (es) |
| AR (1) | AR074558A1 (es) |
| AU (1) | AU2009324358A1 (es) |
| BR (1) | BRPI0922714A2 (es) |
| CA (1) | CA2743557A1 (es) |
| CO (1) | CO6390036A2 (es) |
| CR (1) | CR20110302A (es) |
| DO (1) | DOP2011000164A (es) |
| EA (1) | EA201170801A1 (es) |
| EC (1) | ECSP11011118A (es) |
| IL (1) | IL212948A0 (es) |
| MX (1) | MX2011006221A (es) |
| PE (1) | PE20110772A1 (es) |
| TW (1) | TW201026708A (es) |
| WO (1) | WO2010066840A1 (es) |
| ZA (1) | ZA201104041B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014008065A2 (pt) * | 2011-10-03 | 2019-09-24 | Kineta One Llc | tratamento de obesidade e distúrbios relacionados a obesidade por direcionamento farmacológico de canais de potássio kv1.3 |
| WO2014067861A1 (en) * | 2012-10-29 | 2014-05-08 | F. Hoffmann-La Roche Ag | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel |
| TWI698438B (zh) | 2015-03-13 | 2020-07-11 | 德商４Ｓｃ製藥公司 | Ｋv１.３抑制劑及其醫學應用 |
| TWI701249B (zh) | 2015-03-13 | 2020-08-11 | 德商４Ｓｃ製藥公司 | Ｋv１.３抑制劑及其醫學應用 |
| CN109053751A (zh) * | 2018-08-30 | 2018-12-21 | 成都海博锐药业有限公司 | 具有螺环结构的fxr调节剂 |
| US20220356176A1 (en) * | 2019-06-12 | 2022-11-10 | The Johns Hopkins University | Kv11.1-3.1 INHIBITING METHODS AND COMPOSITIONS |
| KR20220079575A (ko) * | 2019-10-07 | 2022-06-13 | 디.이. 쇼우 리서치, 엘엘씨 | Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로비시클릭 화합물 |
| CN111574537B (zh) * | 2020-05-20 | 2022-11-15 | 成都药明康德新药开发有限公司 | 叔丁基-8-氧杂-3,11-二氮杂螺[5.6]十二烷-3-甲酸基酯的合成方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303637B1 (en) | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
-
2009
- 2009-12-09 AR ARP090104760A patent/AR074558A1/es unknown
- 2009-12-09 TW TW098142079A patent/TW201026708A/zh unknown
- 2009-12-10 EA EA201170801A patent/EA201170801A1/ru unknown
- 2009-12-10 WO PCT/EP2009/066836 patent/WO2010066840A1/en active Application Filing
- 2009-12-10 EP EP09765127A patent/EP2376501A1/en not_active Withdrawn
- 2009-12-10 KR KR1020117016047A patent/KR20110110165A/ko not_active Application Discontinuation
- 2009-12-10 MX MX2011006221A patent/MX2011006221A/es not_active Application Discontinuation
- 2009-12-10 BR BRPI0922714A patent/BRPI0922714A2/pt not_active IP Right Cessation
- 2009-12-10 CN CN2009801494792A patent/CN102333782A/zh active Pending
- 2009-12-10 AU AU2009324358A patent/AU2009324358A1/en not_active Abandoned
- 2009-12-10 CA CA2743557A patent/CA2743557A1/en not_active Abandoned
- 2009-12-10 US US13/133,042 patent/US8575148B2/en not_active Expired - Fee Related
- 2009-12-10 PE PE2011001198A patent/PE20110772A1/es not_active Application Discontinuation
- 2009-12-10 JP JP2011540106A patent/JP2012511546A/ja active Pending
-
2011
- 2011-05-17 IL IL212948A patent/IL212948A0/en unknown
- 2011-05-31 ZA ZA2011/04041A patent/ZA201104041B/en unknown
- 2011-05-31 DO DO2011000164A patent/DOP2011000164A/es unknown
- 2011-06-03 CR CR20110302A patent/CR20110302A/es not_active Application Discontinuation
- 2011-06-08 CO CO11070889A patent/CO6390036A2/es not_active Application Discontinuation
- 2011-06-09 EC EC2011011118A patent/ECSP11011118A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP11011118A (es) | 2011-07-29 |
| BRPI0922714A2 (pt) | 2016-01-05 |
| EP2376501A1 (en) | 2011-10-19 |
| CN102333782A (zh) | 2012-01-25 |
| US20110237569A1 (en) | 2011-09-29 |
| JP2012511546A (ja) | 2012-05-24 |
| KR20110110165A (ko) | 2011-10-06 |
| CA2743557A1 (en) | 2010-06-17 |
| IL212948A0 (en) | 2011-07-31 |
| US8575148B2 (en) | 2013-11-05 |
| CR20110302A (es) | 2011-10-27 |
| WO2010066840A1 (en) | 2010-06-17 |
| EA201170801A1 (ru) | 2011-12-30 |
| PE20110772A1 (es) | 2011-10-19 |
| CO6390036A2 (es) | 2012-02-29 |
| TW201026708A (en) | 2010-07-16 |
| ZA201104041B (en) | 2012-11-28 |
| AU2009324358A1 (en) | 2011-06-23 |
| MX2011006221A (es) | 2011-06-28 |
| DOP2011000164A (es) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074558A1 (es) | Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3 | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| PE20081776A1 (es) | Moduladores 2-aminopirimidina del receptor histamina h4 | |
| PE20140011A1 (es) | Compuestos y composiciones novedosos para la inhibicion de nampt | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| BR112015032637A2 (pt) | derivados de pirrolopiridina ou pirazolopiridina | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| CU20130116A7 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| AR076850A1 (es) | Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa. | |
| AR059428A1 (es) | Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende. | |
| AR050914A1 (es) | Agonista receptor de vasopresina peptidico | |
| EA200970704A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ | |
| AR079467A1 (es) | Derivados heterociclicos nitrogenados de etinilo, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para tratar y/o prevenir enfermedades cognitivas o esquizofrenia. | |
| PE20170703A1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos | |
| ECSP14013296A (es) | Derivados de etinilo | |
| PE20120657A1 (es) | Compuesto para el tratamiento de trastornos metabolicos | |
| AR110241A1 (es) | Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos | |
| AR086024A1 (es) | Derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina carboxamidas | |
| PE20141940A1 (es) | Compuestos triciclicos, composiciones que los comprenden y usos de los mismos | |
| PE20110206A1 (es) | Derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR077960A1 (es) | Derivados de benzamida n-sustituidos como inhibidores del transportador de glicina 1 (glyt-1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |